ARS Pharmaceuticals (SPRY) Earnings Date & Reports

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SPRY is expected to report earnings to fall 170.44% to -33 cents per share on May 19

ARS Pharmaceuticals SPRY Stock Earnings Reports

Q1'25

Est.

$-0.34

Q4'24

Beat

by $0.61

Q3'24

Missed

by $0.06

Q2'24

Missed

by $0.01

Q1'24

Missed

by $0.01

The last earnings report on March 20 showed earnings per share of 47 cents, beating the estimate of -12 cents. With 1.55M shares outstanding, the current market capitalization sits at 1.46B.

View a ticker or compare two or three

Compare

SPRY